LIFE News and Press, aTyr Pharma Inc. From 11/11/20

Peer-reviewed paper supports aTyr’s antibody program . Research conducted in collaboration with AbCellera Biologics, Inc. SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery an...

Discovery advances the understanding of extracellular tRNA synthetase pathways . Findings may contribute to the development of new therapeutic s to treat cancer and fibrosis . SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. ...

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report third quarter 2020 financial results and provide ...

The following slide deck was published by aTyr Pharma, Inc. in conjunction with this event. For further details see: aTyr Pharma (LIFE) Investor Presentation - Slideshow

Collaboration with leading expert Dr. Robert Gemmill will support the company’s neuropilin-2 (NRP2) antibody program in oncology . SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in...

SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Offi...

ATyr Pharma (LIFE) has completed enrollment of 32 subjects in Phase 2 clinical trial of its lead therapeutic candidate, ATYR1923 in hospitalized COVID-19 patients with severe respiratory complications who do not require mechanical ventilation.The subjects enrolled in the trial were ...

Top line results are expected in the fourth quarter of 202 0 . Trial evaluating the preliminary safety and efficacy of ATYR1923 vs placebo has exceeded enrollment . SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasd...

SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will participate in two upcoming virtual investor ev...

ATyr Pharma (NASDAQ: LIFE )   announced that its partner Kyorin Pharmaceutical, a wholly owned subsidiary of Kyorin Holdings has dosed the first subjects in a Phase 1 trial of aTyr’s lead therapeutic candidate ATYR1923. More news on: aTyr Pharma, Inc., Healthcare stocks news ...